Multiple Myeloma: Current Advances and Future Directions

Publication date: Available online 1 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Thomas Martin, Carol Ann HuffAbstractThere have been many advances over the past decade which have dramatically changed the way we evaluate and treat patients with multiple myeloma. These advances have more than doubled the average survival for patients with multiple myeloma and have been paramount to an improved quality of life. Herein, we highlight recent changes to response assessment definitions, provide a review of minimal residual disease (MRD) testing and describe how may MRD testing may affect future goals of therapy. The evolving data from trials assessing novel combinations for frontline therapy and for the treatment of relapsed disease will be reviewed. We will present the preliminary data from the two most promising novel agents, both of which may soon be FDA approved for patients with relapsed multiple myeloma. Finally, we will examine the exciting early data from phase I clinical trials investigating novel immunotherapeutics in refractory myeloma including antibody drug conjugates, dual-targeted T-cell engaging antibodies and chimeric antigen receptor T-cells.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research